PFM
LXEO icon

Privium Fund Management’s Lexeo Therapeutics LXEO Stock Holding History

Privium Fund Management’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$722K Sell
155,000
-50,000
-24% -$270K 0.13% 50
2026
Q1 		$1.18M Buy
205,000
+12,450
+6% +$88.2K 0.25% 41
2025
Q4 		$1.91M Buy
192,550
+194
+0.1% +$1.77K 0.35% 33
2025
Q3 		$1.28M Buy
192,356
+14,000
+8% +$67.7K 0.23% 38
2025
Q2 		$753K Buy
178,356
+18,158
+11% +$59.7K 0.16% 39
2025
Q1 		$556K Buy
160,198
+22,083
+16% +$97.8K 0.14% 40
2024
Q4 		$909K Buy
+138,115
New +$1.09M 0.21% 35

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Privium Fund Management's LXEO Position: Q2 2026 in Review

Privium Fund Management reduced its Lexeo Therapeutics (LXEO) stake by 24% in Q2 2026, selling an estimated $270K and leaving 155,000 shares worth $722K. The position accounts for 0.13% of the portfolio, ranked #50.

Privium Fund Management first reported a position in LXEO in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.91M in Q4 2025. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Privium Fund Management held 155,000 shares of Lexeo Therapeutics worth $722K as of Q2 2026.
  • Privium Fund Management sold 50,000 Lexeo Therapeutics shares in Q2 2026, an estimated $270K.
  • Lexeo Therapeutics made up 0.13% of Privium Fund Management's portfolio in Q2 2026, its #50 holding.
  • Privium Fund Management first reported a position in Lexeo Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Privium Fund Management's Lexeo Therapeutics position peaked at $1.91M in Q4 2025.
  • 141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Privium Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.